Low Float Biotech Stock. Huge Potential. The Setup Is Here. ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from SmallCaps Daily.
One drug. Multiple deadly viruses. See why this under-the-radar firm is gaining attention. As U.S. measles vaccination rates continue to fall, Stanford scientists now warn the virus could become endemic within just a few years. In a world still reeling from the COVID-19 pandemic, a resurgence of viral threats is raising urgent alarm—and opportunity. But one small-cap biotech company is preparing to lead a counterattack. NanoViricides, Inc. (NYSE: NNVC) is a clinical-stage company developing revolutionary broad-spectrum antiviral drugs that could potentially target a wide range of high-risk viruses, including measles, RSV, influenza, long COVID, and more. Why This Could Matter to Investors Now: - NV-387 has demonstrated potential to combat 90–95% of known human pathogenic viruses
- The company has begun testing against measles in preclinical models
- There are currently no approved treatments for RSV or measles
- NV-387’s animal model results for RSV showed complete viral clearance
- Float under 16M and a market cap under $30M could fuel big moves if demand spikes The market has already taken notice:
📈 Recently broke past all major technical moving averages
📈 Recently hit a 6-month high  Why the Broader Market Opportunity Is Even Bigger: The global biotech market was valued at $1.55 trillion in 2023 and is projected to reach $3.88 trillion by 2030. With health systems under pressure and virus threats on the rise, antiviral innovation is now a priority sector for public and private investment worldwide. NanoViricides may be positioned to ride that wave. This could be a rare opportunity to catch a tiny biotech firm just as it steps onto a bigger stage—with real science, real trials, and real momentum. Get the full report on NNVC here → |
Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $5,500 and was received/will be received from Interactive Offers. This compensation should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) and Interactive Offers. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 06/13/2025. Behind the Markets
Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.
You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. |
|
